Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department

Plain-language summary

This study examines the value of procalcitonin (PCT) as a diagnostic marker of bacterial infection in patients admitted to the internal medicine department for fever and/or an inflammatory syndrome. It enrolled patients aged 18 and older with a fever above 38.5°C and/or elevated CRP. It was conducted as a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Centre Hospitalier Universitaire, Amiens

Intervention

Procalcitonin (PCT) as a diagnostic marker of bacterial infection

Start date

2/11/2016

Estimated completion

10/18/2016

Countries

France

Related genes

Locations

• Amiens, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients aged 18 or over hospitalized in the internal medicine department at Amiens University Hospital, presenting with fever (\>38.5°C) and/or inflammatory syndrome (CRP \>5 mg/l) and having given their consent will be included.

Exclusion Criteria:

* Haemodialyzed patients.
* Age under 18.
* Legal guardianship.
* Refusal by the patient, or inability to give consent.
* Patients on antibiotics for more than 12 hours at the time of the PCT assay (the half-life of PCT is 22 hours, and the level falls rapidly when antibiotics are administered).
* PCT assays more than 12 hours after hospitalisation.